In contrast, there was both a significant difference in PARP-1 tracer localization (mean percent injected activity per gram) for the treated group between the initial and latter scan dates (P < 0.01); as well as a measurable difference between the control and treated tumor uptake at day 6 (P < 0.05). This evidence concerns the gene PARP1 and neoplasm.